Completing the Arc: Targeted Inhibition of RET in Medullary Thyroid Cancer

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

(2011) Samuel A. Wells et al.   JOURNAL OF CLINICAL ONCOLOGY

The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells

(2010) D. Vitagliano et al.   ENDOCRINE-RELATED CANCER

Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

(2010) Samuel A. Wells et al.   JOURNAL OF CLINICAL ONCOLOGY

Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas

(2009) M M Moura et al.   BRITISH JOURNAL OF CANCER

Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association

(2009) Richard T. Kloos (Chair) et al.   THYROID

Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474

(2008) Francesca Carlomagno et al.   ENDOCRINE-RELATED CANCER

A Phase II Study of Gefitinib in Patients with Advanced Thyroid Cancer

(2007) Nathan A. Pennell et al.   THYROID